The honest bottom line comes first: CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone that holds no marketing approval from the FDA, the EMA, or any comparable regulator for human use, so no validated dosing or administration protocol exists for it. The figures that circulate trace to one of two sources, a handful of early-phase research studies run under supervision or anecdotal forum reports that carry no evidentiary weight, and neither produces a usage standard. What the literature and community reporting do describe consistently is the shape of handling, two molecular forms, a subcutaneous route, and frequent pairing with a secretagogue such as Ipamorelin, all of it documented here for awareness rather than as guidance.
Because CJC-1295 has never completed the clinical-trial pathway that produces an approved label, no validated human dosing protocol exists, and every circulating figure is either supervised-study data or unverified anecdote, neither of which constitutes medical guidance.
The absence of a dosing standard is a direct consequence of regulatory status, not an oversight waiting to be corrected. CJC-1295 has never been approved as a therapeutic medicine by the FDA, the EMA, or any equivalent national regulator, and circulating material is generally sold under research-use-only or not-for-human-use labeling, which legally signals it has not been evaluated for medical administration. A settled human dosing standard only emerges when a compound completes the full clinical-trial pathway, including the late-phase safety and efficacy studies CJC-1295 has not been carried through.
CJC-1295 carries no approval from the FDA, the EMA, or any equivalent regulator, which legally means there is no approved label and therefore no validated dosing or administration protocol of the kind that exists for a cleared medicine.
The single variable behind the wildly different administration frequencies reported for CJC-1295 is whether the molecule carries a drug affinity complex (DAC). The DAC is a chemical modification that lets the peptide bind reversibly to serum albumin in the bloodstream, shielding it from rapid enzymatic breakdown and extending its functional half-life from minutes to a span measured in days. The version without DAC, frequently sold as modified GRF 1-29, lacks that protection and is cleared quickly, with a half-life on the order of roughly half an hour.
| Property | CJC-1295 with DAC | CJC-1295 without DAC (modified GRF 1-29) |
|---|---|---|
| Half-life | Measured in days | Roughly half an hour |
| Reported frequency | Far less frequent | More frequent |
| Stated rationale | A single exposure persists | Reported to chase the natural growth-hormone pulse |
Because the DAC form's half-life is measured in days while the non-DAC modified GRF 1-29 form clears in roughly half an hour, the literature reports the two as administered on entirely different frequencies, and a dose figure for one form cannot be sensibly transferred to the other.
In both the research literature and informal community reporting, CJC-1295 begins as a freeze-dried lyophilized powder that must be reconstituted into liquid before it can be drawn into a syringe. The diluent described is typically bacteriostatic water, chosen because its preservative content allows a reconstituted vial to be kept for a period without immediate microbial spoilage. The route consistently described is subcutaneous injection, into the fat layer just beneath the skin rather than into muscle or a vein, which is the standard route documented for this class of growth-hormone secretagogue.
The route documented across both research and community sources is subcutaneous injection of a bacteriostatic-water-reconstituted solution, and because the resulting concentration depends entirely on powder-to-water ratio, the volume corresponding to any reported dose is a frequent source of measurement error outside a controlled setting.
Two very different categories of numbers circulate for CJC-1295, and conflating them is a frequent error. The first comes from a small set of early-phase research studies, mostly on the DAC form, that administered the compound to supervised subjects and measured effects on growth-hormone and IGF-1 levels, sometimes expressing exposure relative to body weight, which is what gives those figures any evidentiary standing. The second is the body of anecdotal figures on forums and in informal reports, self-reported, unverified, inconsistent from source to source, and tied to no standardized measurement of outcome or safety.
The published evidence for CJC-1295 dosing is thin and drawn from supervised early-phase studies, while the informal community figures are unverified anecdote with no standardized outcome measure, so any specific number reported for either is background context rather than a target with evidentiary support.
CJC-1295 acts as an analogue of growth-hormone-releasing hormone, stimulating the pituitary through the GHRH receptor pathway, whereas a ghrelin mimetic such as Ipamorelin works through a separate receptor, the growth-hormone secretagogue receptor that ghrelin normally targets. Because the two operate through complementary mechanisms, community and research commentary often describes pairing them on the theory that engaging both pathways at once produces a larger or more pulse-like effect than either alone. That theoretical synergy carries a real interpretive cost, however, because attributing any benefit or adverse event to a specific substance becomes far harder once two unapproved compounds are taken together.
CJC-1295 is reported alongside Ipamorelin because the two act through complementary receptor pathways and are theorized to produce a larger pulse-like effect together, but this pairing is reported convention rather than a validated protocol, and combining two unapproved compounds makes any benefit or adverse event impossible to attribute to a single substance.
Peptides like CJC-1295 are distributed in a freeze-dried lyophilized state because removing the water dramatically improves stability during shipping and storage, whereas in solution these molecules degrade comparatively quickly. The published handling description keeps the dry powder cold and protected from light and moisture before use, while the reconstituted liquid is described as refrigerated and used within a limited window, since once it is back in solution the degradation clock restarts. This matters because a degraded peptide loses potency, which means any assumed dose silently becomes inaccurate as the material breaks down, a problem invisible without analytical testing.
The documented handling for a lyophilized peptide like CJC-1295 keeps the dry powder cold and dark and limits the refrigerated reconstituted vial to a short window, because once in solution the molecule degrades silently, eroding the accuracy of any assumed dose without analytical testing to reveal it.
Self-administering an unapproved injectable peptide carries hazards that exist on several levels at once, and the most consequential is what remains unknown. At the local level, any subcutaneous self-injection risks injection-site reactions, bruising, and infection, with that risk rising sharply when material is prepared without sterile technique. At the systemic level, the compound's purpose is to push growth-hormone and downstream IGF-1 signaling, and chronically elevating those is theoretically linked to fluid retention, joint discomfort, impaired glucose handling, and concern about stimulating abnormal tissue growth, concerns that remain mechanistic precisely because the compound has not been studied long enough to map its real long-term profile.
Self-administration of CJC-1295 layers local injection hazards and theoretical systemic effects on growth-hormone and IGF-1 signaling on top of an essentially uncharacterized long-term safety profile, because the compound has not been carried through the late-phase trials that would map what sustained use does over years.
Every reported dosing figure for CJC-1295 rests on an assumption that the vial actually contains the labeled amount of a pure compound, and for an unapproved peptide sold outside a regulated supply chain that assumption is unsupported. Without enforced manufacturing standards, the actual quantity of peptide can differ from the label, the material can be underfilled, degraded, or mislabeled, and it can carry impurities, residual synthesis reagents, endotoxins, or outright contaminants. This directly undermines the meaning of any precise dose, since a number is only as accurate as the concentration it is measured against, and if that concentration is unknown or wrong, the figure is illusory.
Because an unapproved peptide sold outside a regulated supply chain has no guaranteed identity, purity, or concentration, sourcing uncertainty sits underneath every dosing figure for CJC-1295, and a number measured against an unknown concentration is illusory regardless of how precise it appears.
Educational use only. This article describes what the published scientific and clinical literature reports about CJC-1295. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
